AUTHORS
Yazeed Sawalha, MD, Subodh Bhatta, PhD2, Jordan Lundberg, PharmD3, Sonia Godbole, MD4, Daniel Clancy Trotier, MD5, Kathryn Lurain, MD, MPH6, Yun Choi, MD7, Audrey Sigmund, MD8, Timothy J Voorhees, MD,MSc9, David Bond, MD, BS10, John Reneau, MD, PhD11, Jonathan Brammer, MD12, Aseel Alsouqi, MD13, Seema Ali Bhat, MD14, Kerry A. Rogers, MD15, Jennifer A. Woyach, MD16, Robert A Baiocchi, MD, PhD17, Lapo Alinari, MD, PhD18, Kami Maddocks, MD19, Beth Christian, MD20, Francesca Cottini, MD21, Abdullah Khan, MBBS22, Zeinab El Boghdadly, MD23
AFFILIATIONS
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
10 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
15 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
16 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
17 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
18 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
19 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
20 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
21 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
22 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
23 Atrium Health, Charlotte, North Carolina, United States
ABSTRACT
Introduction: CMV incidence and risk factors during CD3xCD20 bispecific antibody (BsAb) therapy in lymphoma are poorly defined due to non-standardized surveillance and reliance on nonspecific, symptom-driven testing. Because patients (pts) with lymphoma often lack robust antibody responses, the utility of baseline CMV IgG serostatus in predicting infection risk is unclear. We implemented a CMV surveillance protocol in 10/2024 for pts receiving standard-of-care CD3xCD20 BsAb at a US academic center to determine CMV infection incidence and risk factors.
Methods: CMV-IgG was checked at baseline and blood CMV PCR on day 1 of cycles 1-6, regardless of serostatus. Monitoring continued in PCR-positive pts until 2 consecutive negative results. Blood CMV DNA PCR quantitation threshold was 34.5 IU/mL. We defined CMV DNAemia as any detectable CMV DNA; CMV reactivation as CMV DNAemia ≥34.5 IU/mL; and clinically significant CMV infection (csCMVi) as CMV DNAemia requiring preemptive therapy or end-organ disease. The protocol provided guidelines for CMV treatment (tx) based on levels (≥1000 IU/mL) and symptoms.
Results: We included 83 pts: median age 71 years, 68% male. Histologies were large B-cell (n=53, 64%), follicular (n=19, 23%), mantle cell (n=7, 8%), and others (n=4, 5%). Pts received glofitamab (n=45, 54%), epcoritamab (n=22, 27%), or mosunetuzumab (n=16, 19%); 44 (53%) as monotherapy and 39 (47%) in combination (combo; including GemOx n=22 and polatuzumab n=9). Median number of prior therapies was 3, including prior CAR-T (n=24, 29%), autologous stem cell transplant (SCT) (n=7, 8%), and allogeneic SCT (n=2, 2%). All received acyclovir/valacyclovir prophylaxis. Any-grade infection occurred in 40 pts (48%) and cytokine release syndrome (CRS) in 35 (42%); 9 (11%) received tocilizumab.
Baseline CMV IgG was positive in 48/80 (60%) pts. At baseline, 5 pts (6%) had CMV DNAemia, including 3 (4%) with CMV reactivation (79-375 IU/mL). Of 78 pts with undetectable baseline CMV, 14 (18%) pts developed CMV DNAemia: 11 (79%) received BsAb combo; 3 (21%) had prior CAR-T (n=2), autoSCT (n=1), and/or alloSCT (n=1). The cumulative incidence of 1st CMV DNAemia at 1 and 6 months was 6.5% (95%CI 0.8-11.9) and 20.0% (95%CI 9.1-29.6). CMV DNAemia resolved in 42% (8/19) after a median of 25 days, including in 5 pts without any tx (all with peak levels <34.5 IU/mL).
Of 80 pts with baseline CMV levels ≤34.5 IU/ML, 9 (11%) pts developed CMV reactivation: 7 (78%) on BsAb combo (GemOx n=5), 2 (22%) had prior CAR-T ± auto/alloSCT. The cumulative incidence at 1, 3, and 6 months was 3.8% (95%CI 0-7.9), 7.9% (95%CI 1.6-13.7), and 12.7% (95%CI 3.6-21.0). The median peak CMV reactivation level was 157 IU/mL (range 38-2210) and median time to peak was 84 days (range 42-224). csCMVi occurred in 6 pts (7%), including 2 with baseline CMV DNAemia with a median peak level of 150 IU/mL (range 55-2210); all received valganciclovir for a median of 25 days. No CMV end-organ disease or deaths occurred. One pt required a BsAb dose delay. 1-year overall survival was lower among pts with CMV reactivation compared to those without (18% vs 69%; HR 3.3, 95% CI: 1.3–7.9, p=.006), largely driven by higher non-lymphoma-related deaths (25% [3/12] vs 10% [7/71]), while difference in progression-free survival did not reach statistical significance (25% vs 52% HR 1.6, p=.26).
Among IgG-positive at-risk pts, 29.5% (13/44) developed CMV DNAemia and 15.2% (7/46) developed CMV reactivation. Only 1/32 (3%) IgG-negative pts developed CMV DNAemia. The CMV IgG sensitivity and negative predictive value (NPV) for CMV reactivation were 88.9% and 96.9%. In univariable analysis, BsAb combo vs monotherapy was the only factor associated with higher risk of CMV reactivation (HR 5.6, 95%CI 1.1–27.4, p=.035); other evaluated factors included age, BsAb type, prior CAR T, CRS, receipt of tocilizumab, and baseline and day 30 neutrophil and lymphocyte counts.
Conclusions: CMV surveillance during CD3xCD20 BsAb tx identified a 6-month cumulative incidence of 12.7% for CMV reactivation and 7% for csCMVi. No CMV end-organ disease occurred. CMV IgG seronegativity had a high NPV for subsequent infection. Combination regimens carried a significantly higher risk of CMV reactivation. Further studies are required, but initial data support CMV surveillance in seropositive pts receiving CD3xCD20 BsAbs, especially amid expanding combination treatment approaches.
DISCLOSURES
Yazeed Sawalha, MD: BeOne - Research Funding; AbbVie - Research Funding; Genmab - Research Funding; BeOne - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); ADC - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)